BIONEWS
Lilly filed six new federal suits the same day it asked platforms, payment processors, and federal regulators to sever the supply chain for retatrutide, a Phase 3 obesity drug that isn't approved in any country.
Eli Lilly has spent the last year suing peptide vendors that sell its experimental obesity drug retatrutide to consumers. On Aug. 12 the company widened the fight, asking online platforms, payment processors, shipping carriers, and federal regulators to deny service to the trade at large.
Lilly's Aug. 12 press release, mirrored to its investor site, lays out the new ask alongside six new federal complaints, pairing federal suits against named sellers with platform- and payment-level pressure on the broader trade.
Retatrutide isn't on the market. It is a once-weekly injectable in Phase 3 trials for obesity and type 2 diabetes, with no regulatory approval in any country and no lawful path to U.S. compounding. By Lilly's own count, more than 14,000 websites, ads, social posts, and product listings across 100-plus countries have offered it for sale, typically labeled "research use only" and shipped from storefronts in Texas and California to buyers who say they self-inject it for weight loss.
The new ask names four constituencies. Lilly wants online platforms and search engines to take down flagged listings and demote search results, using the same enforcement pipes they already apply to counterfeit goods. From payment processors (credit-card networks, ACH operators, and Stripe-adjacent services), Lilly wants transactions for the named vendors stopped. From shipping and logistics carriers, Lilly wants parcel handoffs to those defendants refused, along with mislabeled "research peptide" parcels to residential addresses. And from federal regulators, Lilly wants action on the more than 200 referrals it has already made to the FDA, the Department of Justice, state attorneys general, and professional licensing boards.
The six new federal suits filed the same day operationalize the seller-side fight. According to BioPharma Dive's filing walk-through, Lilly sued Aesthetic Envy Cosmetic Centers (Northern District of California), Astra LLC d/b/a Astra Peptides (Western District of Texas), Legendary Peptides (Eastern District of Texas), Striker Pharmacy (Southern District of Texas), Texas Peptides Inc. (Western District of Texas), and Lone Star Peptide Co. (Southern District of Texas). No defendant comment was available at filing.
Lilly says the cumulative tally of its enforcement has now hit 14,000-plus flagged listings in 100-plus countries and more than 200 individual referrals to U.S. agencies. Both numbers are company-reported and haven't been independently audited. The release also leans on the FDA's existing drug alert on unapproved GLP-1 products, which already calls retatrutide sales to consumers illegal, says it cannot lawfully be compounded, and warns that "research-use only" products "are of unknown quality and may be harmful to consumers' health."
The operating environment is harder. HHS under Robert F. Kennedy Jr. has taken a freer-rein posture toward unreviewed substances, and an FDA advisory panel in July 2026 endorsed broader use of six peptides without substantial efficacy evidence. Compounded GLP-1s such as semaglutide and tirzepatide have continued to take share after the FDA declared the shortage resolved, because compounders have refused to stop and the agency hasn't forced them to. Lilly is therefore pursuing sellers and the infrastructure in parallel, while pushing regulators to act on existing referrals.
Past platform-side asks from brand-protection teams at Roche, Pfizer, and Novo Nordisk have produced takedown counts but rarely a sustained drop in listing volume, and payment processors have acted only after a court order. The Lilly release is unusually broad in the constituency it names: search engines, card networks, ACH operators, parcel carriers, and federal agencies in the same breath. It stops short of identifying the specific firms it expects to move first. The first concrete signal will be a named platform removal or a processor-level cutoff, not another defendant.
Lilly says it plans to file for FDA approval of retatrutide in 2027. Each listing on a marketplace and each cleared card transaction is, in the company's view, both a public-safety risk and a drag on the trial that is supposed to put the drug on the legitimate market.